Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Cadrenal Therapeutics Inc CVKD

Healthcare Biotechnology
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients... see more

Recent & Breaking News (NDAQ:CVKD)

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

GlobeNewswire 12 days ago

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

ACCESS Newswire December 30, 2025

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

ACCESS Newswire December 29, 2025

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

GlobeNewswire December 17, 2025

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

ACCESS Newswire December 12, 2025

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

ACCESS Newswire December 12, 2025

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

GlobeNewswire December 11, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

GlobeNewswire December 1, 2025

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

GlobeNewswire November 19, 2025

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

GlobeNewswire September 29, 2025

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

GlobeNewswire September 15, 2025

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Business Wire August 11, 2025

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Business Wire August 5, 2025

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Business Wire June 12, 2025

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Business Wire June 4, 2025

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

Business Wire May 15, 2025

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Business Wire May 8, 2025

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Business Wire April 3, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Business Wire March 13, 2025

Podcasts